Quince Therapeutics, Inc. QNCX on Nasdaq
This company's Exchange Act registration has been revoked
This company's Exchange Act registration as a Municipal Advisor has been revoked
This company's Exchange Act registration as a Municipal Advisor has been cancelled
[+] Company Information
CIK:
0001662774
0001662774
EIN:
90-1024039
90-1024039
LEI:
(CF Office: 03 Life Sciences)
Business address:
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO, CA, 94080
Phone: 415-910-5717
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO, CA, 94080
Phone: 415-910-5717
Mailing address:
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO, CA, 94080
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO, CA, 94080
Category:
Non-accelerated filer
Smaller reporting company
Non-accelerated filer
Smaller reporting company
Former names:
- Cortexyme, Inc. - filings through 2022-08-01
Filings:
354 EDGAR filings since January 5, 2016
354 EDGAR filings since January 5, 2016
Get insider transactions
for this issuer
Get insider transactions
for this reporting owner
Latest Filings (excluding insider transactions)
- April 30, 2025 - SCHEDULE 13G/A: Schedule filed by certain investors to report beneficial ownership of more than 5% of a class of equity securities - amendmentOpen documentClick to Open document FilingOpen filingClick to Open filing
- April 23, 2025 - ARS: Annual Report to Security Holders Open documentClick to Open document FilingOpen filingClick to Open filing
- April 23, 2025 - DEFA14A: Additional definitive proxy soliciting materials and Rule 14(a)(12) material Open documentClick to Open document FilingOpen filingClick to Open filing
- April 23, 2025 - DEF 14A: Other definitive proxy statements Open documentClick to Open document FilingOpen filingClick to Open filing
- April 9, 2025 - PRE 14A: Other preliminary proxy statements Open documentClick to Open document FilingOpen filingClick to Open filing
Selected Filings
[+] 8-K (current reports)
- March 24, 2025 - 8-K: Current report Open documentClick to Open document FilingOpen filingClick to Open filing **Earnings release**
- 2.02 - Results of Operations and Financial Condition
- 9.01 - Financial Statements and Exhibits
[+] 10-K (annual reports) and 10-Q (quarterly reports)
- March 24, 2025 - 10-K: Annual report for year ending December 31, 2024Open documentClick to Open document FilingOpen filingClick to Open filing
- November 13, 2024 - 10-Q: Quarterly report for quarter ending September 30, 2024Open documentClick to Open document FilingOpen filingClick to Open filing
- August 13, 2024 - 10-Q: Quarterly report for quarter ending June 30, 2024Open documentClick to Open document FilingOpen filingClick to Open filing
- May 13, 2024 - 10-Q: Quarterly report for quarter ending March 31, 2024Open documentClick to Open document FilingOpen filingClick to Open filing
[+] Proxy (annual meeting) and information statements
- April 23, 2025 - DEF 14A: Other definitive proxy statements Open documentClick to Open document FilingOpen filingClick to Open filing
- April 9, 2025 - PRE 14A: Other preliminary proxy statements Open documentClick to Open document FilingOpen filingClick to Open filing
[+] Ownership disclosures
- Insider transactions
- February 11, 2025 - 4: Statement of changes in beneficial ownership of securities Open documentClick to Open document FilingOpen filingClick to Open filing
- February 11, 2025 - 4: Statement of changes in beneficial ownership of securities Open documentClick to Open document FilingOpen filingClick to Open filing
- February 11, 2025 - 4: Statement of changes in beneficial ownership of securities Open documentClick to Open document FilingOpen filingClick to Open filing
- Beneficial ownership (Schedule 13D and 13G)
- April 30, 2025 - SCHEDULE 13G/A: Schedule filed by certain investors to report beneficial ownership of more than 5% of a class of equity securities - amendmentOpen documentClick to Open document FilingOpen filingClick to Open filing
- February 18, 2025 - SCHEDULE 13G/A: Schedule filed by certain investors to report beneficial ownership of more than 5% of a class of equity securities - amendmentOpen documentClick to Open document FilingOpen filingClick to Open filing
- February 14, 2025 - SCHEDULE 13G: Schedule filed by certain investors to report beneficial ownership of more than 5% of a class of equity securitiesOpen documentClick to Open document FilingOpen filingClick to Open filing
Filings
| Form type | Form description | Filing date | Reporting date |
|---|
0
Showing 1 to 25 of 354 entries
Data source:
CIK0001662774.json
There is no filings data for
this organization
Investor Resources
How to Use EDGAR
Learn how to use EDGAR to research public filings by public companies, mutual funds, ETFs, some annuities, and more.
Before you Invest, Investor.gov
Get answers to your investing questions from the SEC's website dedicated to retail investors
